Pfizer’s Biosimilars Top $2.3bn In 2021
Biosimilars Business Expands By Over 50%; Sterile Injectables Grow To $5.7bn
Pfizer has continued to report growth in its biosimilars segment, with sales up by more than 50% in 2021 to $2.3bn. Meanwhile, a more modest increase has also been seen in the company’s sterile injectables business.
